Measuring Excipient-Market Growth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Excipient-Market Growth
Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.


Pharmaceutical Technology


USP water. BCC Research classifies USP water as a general chemical in its analysis of the global excipient market. USP water includes water for injection (WFI) and purified water. Water must comply with USP standards for chemical purity and microbial content (i.e., < 0.25 ppm of endotoxins). WFI accounts for 76.5% of the USP water market, or $52 million, and purified water 23.5%, or $16 million (1).

Pharmaceutical grades of water used in drug-process applications (i.e., enema and medical-irrigating fluids) and other than those used to formulate excipients are excluded from the analysis. Also excluded is water used as: a pharmaceutical manufacturing process aid (i.e., wet granulation); a solvent for aqueous-based, film-coating materials; a cleaning and rinsing material for containers and closures; a fermentation or cell-culture media ingredient; an extraction and purification solvent; a chemical-reaction solvent; or any other purpose except in a formulated drug-dosage form.

Excipient innovation


Table II: Global excipients market by functional type (1).
Excipients serve various functions within a pharmaceutical formulation. Table II breaks down the global excipient market by functional type on a value and volume basis. An ongoing goal of excipient development is to achieve multifunctionality with a single or a reduced number of excipients in a formulation. Despite increased interest by pharmaceutical companies to add functionality, excipient producers say it is difficult to bring new excipients to market.

"As there is not an approval process for excipients, the introduction of new materials for use as excipients takes a very long time, and most suppliers are not willing to invest as the rewards do not justify the investment for a material new to the industry," explains Tim Bee, senior director of the global pharmaceuticals business at International Specialty Products (ISP, Wayne, NJ).

"The cost of new excipients in terms of the need for toxicology studies is prohibitive for most excipient companies," adds Alen Guy, vice-president of research and development at JRS Pharma (Patterson, NY). "The return on investment is not there, and such a venture needs a 'slam dunk' application to receive senior-level approval."

Wider options

Although introducing new excipients is a slow and costly process, the excipient market is not without innovation. Excipient makers use a strategy of developing excipient blends to achieve multifunctionality and introduce new grades of existing excipients to enhance performance for specified applications. Excipients for orally disintegrating tablets (ODTs) and controlled-release formulations are recent examples.

Orally disintegrating tablets. In September 2007, BASF launched "Ludiflash," a coprocessed excipient consisting of three ingredients: a special grade of mannitol used as a filler; crospovidone used as a superdisintegrant; and a polyvinyl acetate dispersion used as a binder. Ludiflash was specifically developed for the manufacture of ODTs but can also be used as granules or powder in sachets. Because it contains a filler, binder, and disintegrant, only the API and a lubricant are added to the formulation. Colorants and taste-masking agents may also be used.

"Ludiflash offers properties not achievable by simply blending the three ingredients," explains Dr. Ralf Widmaier, marketing manager at BASF SE (Ludwigshafen, Germany). "It offers a wide-processing window and very good hardness and low friability of the tablets at disintegration times within 10–30 s in the mouth without drinking water."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here